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Despite the development of new agents with activity against Gram-positive bacteria, vancomycin remains one of the primary
antibiotics for critically ill septic patients. Because sepsis can alter antimicrobial pharmacokinetics, the development of an ap-
propriate dosing strategy to provide adequate concentrations is crucial. The aim of this study was to prospectively validate a new
dosing regimen of vancomycin given by continuous infusion (CI) to septic patients. We included all adult septic patients admit-
ted to a mixed intensive care unit (ICU) between January 2012 andMay 2013, who were treated with a new vancomycin CI regi-
men consisting of a loading dose of 35 mg/kg of body weight given as a 4-h infusion, followed by a daily CI dose adapted to creat-
inine clearance (CrCL), as estimated by the Cockcroft-Gault formula (median dose, 2,112 [1,500 to 2,838] mg). Vancomycin
concentrations were measured at the end of the loading dose (T1), at 12 h (T2), at 24 h (T3), and the day after the start of therapy
(T4). Vancomycin concentrations of 20 to 30 mg/liter at T2, T3, and T4 were considered adequate. A total of 107 patients (72%
male) were included. Median age, weight, and CrCL were 59 (interquartile range [IQR], 48 to 71) years, 75 (IQR, 65 to 85) kg, and
94 (IQR, 56 to 140) ml/min, respectively. Vancomycin concentrations were 44 (IQR, 37 to 49), 25 (IQR, 21 to 32), 22 (IQR, 19 to
28), and 26 (IQR, 22 to 29) mg/liter at T1, T2, T3, and T4, respectively. Concentrations were adequate in 56% (60/107) of patients
at T2, in 54% (57/105) at T3, and in 73% (41/56) at T4. This vancomycin regimen permitted rapid attainment of target concentra-
tions in serum for most patients. Concentrations were insufficient in only 16% of patients at 12 h of treatment.
Vancomycin remains a primary treatment for infections causedby Gram-positive bacteria resistant to -lactam antibiotics,
including methicillin-resistant Staphylococcus aureus (MRSA),
methicillin-resistant Staphylococcus epidermidis (MRSE), and am-
picillin-resistant enterococci (1). Despite extensive clinical use of
vancomycin over recent years, the optimal dosing strategy for
rapid achievement of therapeutic concentrations still remains a
challenge for physicians. This is of particular interest for patients
with septic shock, who require adequate antibiotic therapy, espe-
cially in terms of drug concentrations, from the early phase of
treatment (2, 3). To rapidly achieve optimal vancomycin concen-
trations in such patients, a loading dose followed by a continuous
drug infusion (CI) has been proposed (4).
Although CI of vancomycin is increasingly used, especially in
the intensive care unit (ICU), there is still a controversy as to
whether this mode of administration provides better results than
standard intermittent drug administration (II). Several studies
have shownno differences in clinical efficacy ormortality between
the two therapeutic strategies in infections with Gram-positive
bacteria (4–6). However, Wysocki et al. (5) demonstrated that CI
allowed faster achievement of target concentrations, presented
less variability in drug concentrations, and resulted in reduced
costs of therapy. Furthermore, a recentmeta-analysis showed that
CI was associated with a significantly lower risk of drug-related
nephrotoxicity than II, despite the use of similar daily doses (6).
Nevertheless, because of significant changes in vancomycin
pharmacokinetics (PK) during critical illness, such as increased
volume of distribution (V) and augmented clearance, the stan-
dard CI regimen (e.g., a loading dose of 15 mg/kg of body weight,
followed by 30 mg/kg over 24 h for patients with normal renal
function) (5) has been associated with inadequate drug concen-
trations in a high proportion of septic patients in the first 2 days of
therapy (7). As such, Roberts et al. (8), using a population PK
analysis, suggested that a vancomycin loading dose of 35 mg/kg,
followed by daily doses adjusted to creatinine clearance (CrCL,
ranging from 7 to 45 mg/kg/day), would rapidly achieve adequate
drug concentrations in critically ill patients. Nevertheless, this ap-
proach has not been prospectively validated yet.
Another important issue concerning vancomycin is that clini-
cal efficacy is best predictedwhen the ratio between the area under
the curve of drug concentrations over 24 h (AUC0–24) and the
MIC for the pathogen isolated (AUC0–24/MIC) exceeds 400 (9–
12). To ensure optimal AUC0–24/MIC ratios, several studies have
proposed target serum drug concentrations between 15 and 30
mg/liter during CI of vancomycin (5, 13–15). Nevertheless, no
study has evaluated the correlation between vancomycin concen-
trations and the achievement of anAUC0–24/MIC ratio of400 in
critically ill patients, in particular during the first day of therapy.
The aim of this study was, therefore, to determine whether a
newly described CI regimen of vancomycin would result in ade-
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quate drug concentrations in critically ill patients in the early
phase of therapy. We also evaluated whether target vancomycin
concentrations could predict optimal AUC0–24/MIC ratios in
these patients.
MATERIALS AND METHODS
Patient population.We included all adult (age,18 years) patients who
were treated with CI of vancomycin, either as monotherapy or combined
with other antibiotics, in our multidisciplinary Department of Intensive
Care between January 2012 and May 2013. In January 2012, we intro-
duced a new vancomycin CI regimen as the standard of care for all pa-
tients. This regimen consisted of a loading dose of 35 mg/kg given over a
4-h infusion period followed by a CI adapted to the CrCL (8), as assessed
using the Cockcroft-Gault equation (CG-CrCL) (16) (Table 1). Total
body weight (TBW) was used to calculate the drug regimen; if not avail-
able in the medical file, TBW was estimated by the attending physician.
This procedure was used because it is routinely used to adjust antibiotic
regimens in our Department. Patients were excluded if they had received
vancomycin in the preceding 48 h or if they were receiving treatment with
any renal replacement therapy or with extracorporeal membrane oxygen-
ation (ECMO). The study protocol was approved by the local Ethics Com-
mittee (Comité d’EthiqueHôpital Erasme—ULB),whichwaived the need
for informed consent, because this regimen and drugmonitoring are con-
sidered routine management in this setting in our department.
Vancomycin therapy. Vancomycin was reconstituted according to
the manufacturer’s guidelines. Serum drug concentrations were mea-
sured in 3-ml blood samples taken at the end of the loading dose (T1), 12
h after the onset of treatment (T2), and 24 h after the onset of treatment
(T3). Nurses recorded the exact sampling time on a computer-based da-
tabase. Serum drug concentrations were also measured daily at 8 am
thereafter (i.e., on day 2, day 3, etc.). Vancomycin concentrations were
determined by a particle-enhanced turbidimetric inhibition immunoas-
say (Dimension XPand; Siemens Healthcare Diagnostics, Newark, DE).
The limit of quantification and the total imprecision of the assay were 0.8
mg/ml and 5%, respectively. The aim of this regimen was to attain
“adequate” serum vancomycin concentrations (i.e., between 20 and 30
mg/liter) at 12 and 24 h. Insufficient or excessive drug concentrations
were defined as20 mg/liter or30 mg/liter, respectively. In the case of
insufficient drug concentrations at T3, a bolus of 500 to 1,000 mg was
given, and the daily dose was increased by 25%. If drug levels were exces-
sive, the CI was discontinued for 4 h, and the daily dose was decreased by
25%.
Data collection. For all patients included, the following data were
recorded: demographics (including weight and body mass index [BMI]),
comorbidities, admission diagnosis, biological and microbiological data,
length of ICU and hospital stays, and ICUmortality. The severity of illness
was assessed by the Acute Physiology and Chronic Health Evaluation
(APACHE) II score (17) on admission for each patient. The Sequential
Organ Failure Assessment (SOFA) score (18) was assessed and recorded
daily. Patients were said to have chronic kidney disease (CKD) when the
estimated glomerular filtration rate was60 ml/min (i.e., CKD stage 3 to
5, not on dialysis) according to recent definitions (19). Treatment with
vasopressor agents or mechanical ventilation was also recorded. We
also determined the CrCL at 24 h of therapy based on urinary creati-
nine excretion (uCrCL [measured in milliliters per minute]), which
was routinely calculated every day as (urinary creatinine concentra-
tion [in milligrams per deciliter]  volume [in milliliters])/(serum
creatinine concentration [in milligrams per deciliter]  duration of
urine collection [in minutes]). Augmented renal clearance was defined as
a uCrCl of130 ml/min (20).
Pharmacokinetic parameters. The AUC of serum vancomycin con-
centrations measured during the first 24 h of treatment was calculated for
each patient using the trapezoidal rule. Vancomycin clearance (CLVAN)
was calculated as (dose rate)/(concentration at 24 h).
Statistical analysis. Statistical analyses were performed using the SPSS
18.0 for Windows NT software package (2004; SPSS Inc., Chicago, IL,
USA). Descriptive statistics were computed for all study variables. A Kol-
mogorov-Smirnov test was used, and histograms and normal quantile
plots were examined to verify the normal distribution of continuous vari-
ables. Discrete variables were expressed as counts (percentages) and con-
tinuous variables as means  standard deviations (SD) or medians
(ranges).Multivariable logistic regressionwas used to assess which factors
were independently associated with insufficient or excessive vancomycin
concentrations at T3; only variableswithP values of0.1 in the univariate
analysis were included in the final model. The sensitivity, specificity, pos-
itive predictive value (PPV), and negative predictive value (NPV) of van-
comycin concentrations of20 mg/liter for predicting an AUC0–24/MIC
ratio of400 were calculated for several MICs. Drug concentrations as-
sociated with the best sensitivity, specificity, PPV, and NPV were identi-
fied. Finally, we divided patients according to the CrCL ranges obtained
using the CG-CrCL or the uCrCL into the following groups: (i) group 1,
for which both CrCL values were within the same range, corresponding to
a particular recommended daily dose (Table 1); (ii) group 2, for which the
uCrCL was higher than the CG-CrCL (i.e., patients at risk of underdos-
ing), and (iii) group 3, for which the CG-CrCLwas higher than the uCrCL
(i.e., patients at-risk of overdosing). Vancomycin concentrations were
compared among these groups using two-way analysis of variance
(ANOVA), followed by a Bonferroni post hoc analysis to evaluate differ-
ences between groups for each time point. A P value of 0.05 was con-
sidered significant.
RESULTS
A total of 107 patients were included during the study period.
Demographic characteristics are shown in Table 2. Most patients
were admitted for medical reasons, with a median APACHE II
score of 19 on admission and a median SOFA score of 6 at the
beginning of the CI. Themost frequent sites of infections were the
lungs and the abdomen (Table 3). Twenty-four of the proven
infections withGram-positive bacteria were due toMRSA,MRSE,
or Enterococcus faecium (there were 60 infections with Gram-neg-
ative bacteria and 23 negative microbiological samples). All pa-
tients were receiving at least one other antimicrobial agent at the
moment when the CI of vancomycin was initiated. Twenty-two
patients (21%) had augmented renal clearance, and 17 (16%) had
a BMI of30.
Themedian loading dose of vancomycinwas 2,650mg, and the
median daily dose was 2,112mg. At T1, T2, and T3,median serum
vancomycin concentrations were 44, 25, and 22 mg/liter, respec-
tively (Table 4). The distributions of vancomycin concentrations
at T1, T2, and T3 are shown in Fig. 1; 17 (16%) and 29 (28%)
patients had drug concentrations of 20 mg/liter at T2 and T3,
respectively. Concentrations were adequate in 56% (60/107) of
patients at T2 and in 54% (57/105) of patients at T3. Levels were
excessive in 28% (30/107) and 17% (19/105) of patients at T2 and
T3, respectively. Consideration of the distribution of drug con-
TABLE 1 Initial daily doses of vancomycin according to estimated
creatinine clearance
CG-CrCLa (ml/min) Daily dose (mg/kg)
150 45
120–150 40
80–119 30
50–69 25
25–50 14
25 (anuria) 7
a Creatinine clearance, estimated using the Cockcroft-Gault formula.
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centrations within the different uCrCL ranges at T3 shows that the
patients with the highest uCrCL values had a greater proportion of
insufficient drug concentrations than the other patients (Fig. 2)
(P 0.02).
The only factors identified as predictors for insufficient serum
concentrations at T3were lower BMI and higher uCrCL (Table 5).
Excessive drug concentrations at T3 were predicted by higher
BMI, lower uCrCL and higher vancomycin concentrations at T1.
Table 6 shows the sensitivity, specificity, PPV, and NPV of vanco-
mycin concentrations for predicting AUC0–24/MIC ratios of
400 for several MICs. For a MIC of 1.0 mg/liter, target serum
vancomycin concentrations of15mg/liter at T3 ensured AUC0–
24/MIC ratios of400 mg/h/liter in all the patients. However, for
MICs of1.5 mg/liter, target serum drug concentrations of25
mg/liter were necessary to ensure that most patients (97%) at-
tained adequate PK targets.
WhenuCrCL andCG-CrCL valueswere compared, 47 patients
were classified in group 1, 13 in group 2, and 47 in group 3 (thus,
60/107 patients would not receive the adequate daily dose if the
CG-CrCL was used). There were significant differences in serum
drug concentrations among the three groups, in particular at T2,
when concentrations in group 2were lower than those in the other
two groups (Fig. 3). Among those patients for whom the CI was
continued after the first day of therapy (n  56), 14 (25%) had
insufficient and 12 (21%) had excessive drug concentrations. Af-
ter adjustment of the drug regimen, only 4 (7%) and 6 (11%)
patients had insufficient and excessive drug concentrations on day
2 of therapy, respectively (P, 0.04 versus T3).
DISCUSSION
In this study,we evaluated a new regimen forCI of vancomycin for
critically ill patients during the first 24 h of therapy, which in-
TABLE 2 Characteristics of patients
Characteristica
Value for patientsb
(n 107)
Age (yr) 59 (48–71)
No. of men/women 77/30
Body wt (kg) 75 (65–85)
Body mass index (kg/m2) 24 (22–28)
No. (%) with comorbidities
COPD/asthma 19 (18)
Heart disease 24 (22)
Diabetes 23 (21)
Chronic renal disease 31 (29)
Liver cirrhosis 7 (6)
Cancer 17 (16)
Corticosteroids 34 (32)
Other immunosuppressive agents 25 (23)
Organ transplantation 17 (16)
No. (%) with medical admission 69 (64)
APACHE II score on ICU admission 19 (13–25)
SOFA score at the onset of therapy 6 (4–9)
No. (%) with septic shock at the onset of therapy 57 (53)
No. (%) on mechanical ventilation at the onset
of therapy
58 (54)
ICU mortality (no. [%]) 24 (22)
a COPD, chronic obstructive pulmonary disease; APACHE, Acute Physiology and
Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; ICU,
intensive care unit.
b Data are presented as counts (percentages) or medians (25th to 75th percentiles).
TABLE 3 Characteristics of infections
Infectiona No. (%) of patients (n 107)
Lung 47 (44)
Abdominal 12 (11)
Urinary 8 (7)
Skin or soft tissue 8 (7)
Catheter related 7 (6)
Neurological 5 (5)
Primary bacteremia 18 (17)
MRSA 10
MRSE 10
Enterococcus faecium 4
a MRSA, methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant
Staphylococcus epidermidis.
TABLE 4 Pharmacokinetic and pharmacodynamic characteristics of
therapy
Characteristica Value for patientsb
Vancomycin concn (mg/liter)
At 4 h (T1) 44 (37–49)
At 12 h (T2) 25 (21–32)
At 24 h (T3) 22 (19–28)c
On day 2 26 (22–30)d
AUC0–24 (mg · h/liter) 771 (644–905)
Drug clearance from 0 to 24 h (mg · h/liter) 3.0 (2.1–3.8)
CG-CrCL (ml/min) 94 (56–140)
uCrCl (ml/min) 82 (43–157)
a CG-CrCL, creatinine clearance according to the Cockcroft-Gault formula; uCrCL,
creatinine clearance determined from urinary elimination.
b Data are presented as medians (25th to 75th percentiles). A total of 107 patients were
evaluated except where otherwise indicated.
c A total of 105 patients were evaluated.
d A total of 56 patients were evaluated.
FIG 1 Distribution of vancomycin concentrations at the end of the loading
dose (T1), at 12 h (T2), and at 24 h after the onset of therapy (T3). The shaded
zone indicates target drug concentrations, assessed at T2 and T3.
Cristallini et al.
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cluded a higher than recommended loading dose and a daily dose
adjusted for renal function. We found that only 16% of patients
had insufficient drug concentrations at 12 h, and 28%at 24 h, after
the initiation of treatment. After a dosing regimen adjustment at
24 h, 90% of the patients in this cohort eventually achieved
minimal target serum drug concentrations within 48 h from the
onset of drug infusion. Importantly, one-quarter of the patients
had excessive serum drug concentrations during the first day of
therapy. The major determinants for insufficient serum concen-
trations were increased BMI and augmented renal clearance. We
also showed that a serumdrug concentration of at least 15mg/liter
at 24 h would ensure an adequate AUC0–24/MIC ratio in all pa-
tients for strains with aMIC of1.0 mg/liter. However, for infec-
tions due to bacteria with MICs of 1.5 mg/liter, serum drug
concentrations of 25 mg/liter would be necessary to achieve
adequate AUC0–24/MIC ratios.
For non-ICU patients with severe MRSA infections, standard
regimens of vancomycin (15 mg/kg followed by 30 mg/kg/day)
given by CI achieved target drug concentrations within 36 h from
the initiation of therapy (5). Nevertheless, recent studies have un-
derlined that for critically ill patients, this drug regimen is associ-
ated with a high proportion of individuals with insufficient drug
concentrations, because of significant changes in vancomycin PK
(7, 21). Ocampos-Martinez et al. found that this standard regimen
resulted in vancomycin concentrations of20 mg/liter in50%
FIG 2 Distribution of vancomycin concentrations at 24 h after the onset of
therapy (T3), according to different creatinine clearance valuesmeasured from
daily urine collection. The shaded zone indicates target drug concentrations.
Chi-square analysis for trend yielded a P value of 0.02. Lowercase letters a, b,
and c above data indicate significant differences. Individual analyses showed
significant differences (P 0.05) from vancomycin concentrations at a creat-
inine clearance of25ml/min (a), 25 to 50ml/min (b), or 51 to 80ml/min (c).
TABLE 5 Risk factors for insufficient or excessive serum vancomycin concentrations at 24 h of treatment (T3)
Characteristica
Valueb for patients with
vancomycin concns (mg/liter)
of:
P value (20 vs20 mg
of vancomycin/liter)b
Valuec for patients with
vancomycin concns (mg/liter) of:
P value (30 vs30 mg
of vancomycin/liter)c20 (n 29) 20 (n 78) 30 (n 85) 30 (n 22)
Age 56 (37–68) 59 (49–71) 0.07 59 (47–72) 59 (46–70) 0.67
No. (%) male 23 (79) 54 (69) 0.31 63 (74) 14 (64) 0.35
Wt (kg) 56 (65–75) 59 (65–90) 0.007 75 (65–80) 80 (65–95) 0.12
Body mass index (kg/m2) 24 (22–26) 25 (15–27) 0.01 24 (22–28) 28 (24–30) 0.01
No. (%) with:
Medical admission 20 (69) 49 (63) 0.56 54 (64) 15 (68) 0.69
Corticosteroids 7 (24) 27 (35) 0.31 28 (33) 6 (27) 0.58
Neutropenia 1 (3) 9 (12) 0.23 8 (9) 2 (9) 0.51
Organ transplant 2 (7) 15 (19) 0.17 15 (18) 2 (9) 0.51
Cancer 4 (14) 13 (17) 0.72 13 (15) 4 (18) 0.99
COPD/asthma 5 (17) 14 (18) 0.93 14 (17) 5 (23) 0.68
Diabetes 7 (24) 16 (21) 0.69 18 (21) 5 (23) 0.58
Heart disease 7 (24) 17 (22) 0.79 19 (22) 5 (23) 0.65
CKD 7 (24) 24 (31) 24 (28) 7 (32)
Liver cirrhosis 0 (0) 6 (8) 0.99 5 (6) 2 (9) 0.81
APACHE II on admission 20 (15–23) 19 (13–24) 0.97 20 (14–23) 19 (13–23) 0.66
No. (%) in shock 17 (59) 41 (53) 0.63 46 (54) 12 (55) 0.97
No. (%) on mechanical ventilation 18 (62) 40 (51) 0.32 49 (58) 9 (41) 0.25
SOFA score on day 1 6 (3–9) 7 (4–10) 0.91 7 (4–9) 6 (4–10) 0.86
Daily dose of vancomycin (mg/kg) 36.8 (25–42.6) 28.2 (23.5–35.7) 0.19 33.8 (24.0–38.5) 25.8 (25.0–40.0) 0.98
Vancomycin concn (mg/liter) at T1 39 (33–45) 46 (40–50) 0.12 42 (33–47) 50 (46–59) 0.001
No. (%) with respiratory infection 15 32 0.32 39 (46) 8 (36) 0.86
uCrCL (ml/min) 138 (73–178) 64 (33–138) 0.13 97 (51–162) 52 (23–82) 0.02
a CKD, chronic kidney disease; T1, end of loading dose infusion; uCrCL, creatinine clearance measured on daily urine excretion.
b Obtained by univariate analysis. Multivariate analysis found body mass index (odds ratio [95% confidence interval], 0.87 [0.78 to 0.96]) and uCrCL (1.01 [1.00 to 1.02]) to be
predictive of insufficient drug concentrations.
c Obtained by univariate analysis. Multivariate analysis found body mass index (odds ratio [95% confidence interval], 1.15 [1.02 to 1.29]), the vancomycin concentration at T1
(1.06 [1.01 to 1.10]), and uCrCL (0.98 [0.97 to 0.99]) to be predictive of excessive drug concentrations.
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of patients after 24 h of treatment (7). Similarly, De Waele et al.
showed that a fixed loading dose (1,000 g if TBW was 65 kg;
1,500mg if TBWwas65 kg) followed by a CI daily dose of 2,000
mg/24 h was associated with serum drug concentrations of 20
mg/liter for 48%and 39%of patients on days 2 and 3 of treatment,
respectively (21). Some authors have, therefore, suggested alter-
native dosing regimens to rapidly optimize drug concentrations in
such patients. In a small study (n  20), Jeurissen et al. showed
that a loading dose of 1,000 mg followed by a daily dose of 3,000
mg provided adequate vancomycin concentrations (25 mg/liter)
on day 2 of therapy in patients with normal renal function (22).
This regimen has never been prospectively validated. In another
study, Pea et al. analyzed a cohort of 70 patients treated with CI of
vancomycin and proposed two dosing nomograms to achieve
drug concentrations of 15 or 20mg/liter at steady state (48 to 72 h
after the onset of treatment) after a loading dose of 15mg/kg given
over 2 h (14). The performance of these formulas was prospec-
tively validated in a similar cohort (n 63) of patients in the same
study.
However, optimization of vancomycin regimens should aim to
achieve therapeutic concentrationswithin a few hours of the onset
of treatment. With the dosing regimen we tested, we obtained
target serum vancomycin concentrations at 12 h of treatment.
This was achieved using a higher than recommended loading dose
and a daily regimen adjusted to renal function. Similarly, Carri-
cajo et al. reported that a vancomycin regimen based on a loading
dose of 30 mg/kg, followed by 30 mg/kg per day in patients with a
CrCL of 50 ml/min, enabled minimum concentrations of 20
mg/liter to be attained after 24 h of treatment in 13/22 critically ill
patients; all the patients with insufficient serum drug concentra-
tions had CrCLs of120 ml/min (15). Saugel et al. also reported
that the use of a drug regimen based on a loading dose of 20mg/kg
of TBW, followed by a daily regimen ranging from 20 mg/kg (if
renal insufficiency) to 30 mg/kg (if no renal insufficiency), was
associated with insufficient vancomycin concentrations in15%
of patients (n 34); 36% of patients in this cohort had excessive
serum concentrations (23). Thus, an initial loading dose of 30 to
35mg/kg is necessary to achieve target vancomycin ranges rapidly
in critically ill patients. The use of a high loading dose may also
explain the high proportion of patients with “excessive” rather
than “insufficient” drug concentrations. However, the occurrence
of excessive drug concentrations was also lower than in the study
by Saugel et al. (23), probably because of a more precise dose
adjustment according to differentCrCL ranges. The consequences
of excessive serum vancomycin concentrations of short duration
in critically ill patients need to be explored in order to determine
the optimal balance between the advantages of rapid attainment of
adequate therapeutic concentrations and the risks of potentially
toxic concentrations.
The main risk factors predicting inadequate serum vancomy-
cin concentrations were BMI and CrCL. Although drug CL is al-
most linearly correlated with CrCL (7), we found more patients
with insufficient drug concentrations in the lowest and highest
CrCL ranges. This finding is explained mainly by the use of the
CG-CrCL, which may largely underestimate residual renal func-
tion in critically ill patients with augmented renal clearance or
overestimate the degree of acute renal impairment (24). More-
over, some patients have very high renal blood flow and increased
drug CL—so-called augmented renal clearance—which has al-
ready been reported to be a major determinant of low serum an-
tibiotic concentrations in this patient population (20). Concern-
FIG 3 Vancomycin concentrations at different time points in the three
groups, according to the differences in creatinine clearances measured using
the Cockcroft-Gault formula or daily urinary excretion (see Materials and
Methods). Two-way analysis of variance was performed (P 0.02); an asterisk
indicates differences at a specific time point according to the Bonferroni post
hoc analysis.
TABLE 6 Sensitivity, specificity, and positive and negative predictive
values of vancomycin concentrations at T3 for predicting AUC0–24/MIC
ratios of400 at different MICsa
Vancomycin concn (mg/liter)
at T3 and predictive measure
Value (%) for predicting anAUC0–24/
MIC ratio of400 at a MIC (mg/liter)
of:
0.5 1.0 1.5 2.0
15
Sensitivity 95 96 100 100
Specificity 100 100 31 6
PPV 100 100 89 26
NPV 0 20 100 100
20
Sensitivity 78 78 87 94
Specificity 100 100 75 37
PPV 100 100 95 57
NPV 0 4 50 88
25
Sensitivity 37 37 43 70
Specificity 100 100 100 93
PPV 100 100 100 90
NPV 0 2 24 78
30
Sensitivity 21 21 24 44
Specificity 100 100 100 100
PPV 100 100 100 100
NPV 0 1 19 67
a T3, 24 h after the initiation of therapy; AUC0–24/MIC ratio, ratio between the area
under the curve of drug concentrations over the first day of therapy and the MIC.
Cristallini et al.
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ing BMI, several studies have suggested that daily vancomycin
regimens should be administered according to total body weight
(25, 26). However, obese patients are at a high risk of insufficient
drug concentrations (27), and the measurement of at least two
drug concentrations per day, in order to optimize drug regimens
in this setting, has been suggested (26). In our study, low and high
BMIs were significantly associated with excessive and insufficient
drug concentrations, respectively. However, estimated body
weight and height for critically ill patients may be inaccurate by as
much as 11 and 15%, respectively (28); weight prediction errors of
20% were observed in almost 20% of cases. This inaccuracy of
weight and height estimation by ICU staff may lead to the selec-
tion of inappropriate drug regimens for ICU patients; the use of
specific scales or beds that can directlymeasure actual bodyweight
should be considered in order to optimize drug regimens, at least
for patients with BMIs markedly outside normal ranges (29).
Thus, using these PK parameters, which were prospectively col-
lected, reanalysis of the loading and daily drug doses should be
performed in order to understand how to optimize vancomycin
regimens in the extreme ranges of weight and drug CL.
The new dosage regimen tested in this study rapidly attained
target serum vancomycin concentrations of 20 to 30 mg/liter;
however, the pharmacodynamic (PD) index that drives drug ef-
fectiveness is the AUC0–24/MIC ratio, in particular when it is
400 (30). As such, CI may achieve target concentrations more
rapidly, with a lower daily dose, withmore-stable drug concentra-
tions and fewer adverse events, than standard intermittent infu-
sion (5). Although Jeffres et al. showed that serum vancomycin
concentrations were significantly correlated to the AUC/MIC ra-
tio, these data were from non-critically ill patients and could not
be generalized to patients with severe life-threatening infections
(13). In our study, we showed that target concentrations between
20 and 30mg/liter were appropriate, depending on the likelyMIC
for the pathogen. Indeed, with strains forwhich theMICwas1.5
mg/liter, our proposed target concentrations provided adequate
AUC/MIC ratios for all patients. Importantly, with pathogens for
which the MIC is 2 mg/liter or higher, very high daily regimens
and concentrations of vancomycin, which are strongly associated
with the development of renal toxicity, would be required (31);
thus, other anti-MRSA agents may be preferable in this setting.
There are some limitations to our study. First, wemeasured the
total fraction of vancomycin, which is not predictive of the free
concentrations that eventually penetrate tissues and are effective
in treating the infectious process (32). However, measurement of
free concentrations is not available in daily clinical practice, and
PK/PD targets have been defined only on the basis of total con-
centrations. Second, this newCI regimenmay not be applicable to
all ICU patients, since we excluded pediatric patients and those
undergoing extracorporeal therapies. Also, the presence of more
patients with inadequate drug concentrations in the extreme
ranges of CrCL would require another PK analysis and regimen
adjustment, in particular for those with augmented renal clear-
ance. Moreover, since few obese patients were included, and the
proportion of patients with augmented renal clearance was lower
than in other studies including critically ill patients (33, 34), more
patients with insufficient drug concentrations could be expected if
this drug regimen were applied in other settings. This may partly
explain why the overall performance of this dosing scheme was
better than in earlier studies. Third, we scheduled only three sam-
ples to calculate the AUC, which might have been less accurate
than if more samples had been obtained. However, this sampling
was implemented as the standard of care in our department, and
more blood analyses would have been difficult to justify in clinical
practice. Fourth, the AUC in the first 24 h may be much higher
than on subsequent days due to the administration of the loading
dose; thus, target attainment rates on the first day may not reflect
the adequacy of the regimen on subsequent days of therapy. Fifth,
and finally, the CG-CrCL is a poor predictor of CrCl and antibi-
otic CL in critically ill patients (24). Unfortunately, the assessment
of uCrCl was not the standard of care in our institution at the
moment when the study was initiated and could not be imple-
mented for the selection of the initial vancomycin regimen. Mon-
itoring of urinary creatinine excretion over a limited period (e.g.,
2 to 4 h) may be a more accurate option for estimating renal
function and rapidly guiding the choice of antibiotic regimens in
this setting (24, 35).
Conclusions. A new CI dosage regimen for vancomycin en-
abled rapid attainment of target serum drug concentrations in the
majority of critically ill adult patients. To ensure effective dosing,
particular attention should be paid to accurate estimations of
body weight and to renal clearance, since high BMI and aug-
mented renal clearance aremajor determinants of drug underdos-
ing.
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